

**How will
HIV drug
resistance
from PrEP be
monitored and
prevented?**



GEMS provides a comprehensive assessment of HIV drug resistance risk with PrEP use and policy recommendations for the frequency of HIV testing and resistance monitoring for projects implementing PrEP in sub-Saharan Africa.

Find out more at gems.pitt.edu or contact gems@pitt.edu



USAID
FROM THE AMERICAN PEOPLE



GEMS partners include FHI 360, BARC-Lancet Laboratories, University College London and University of Washington/Fred Hutchinson Cancer Research Center.

GEMS PROJECT GOALS

Science

- Comprehensively characterize resistance risk from PrEP trials and demonstration projects.

Modeling

- Identify the most effective and efficient HIV testing and resistance monitoring strategies.

Policy

- Generate evidence-based policy recommendations for HIV diagnostic testing frequency and ARV resistance monitoring.

Rollout

- Monitor seroconverters from PrEP roll-out programs for ARV resistance in selected clinics in countries in sub-Saharan Africa.

GEMS will provide **technical support** for HIV testing and drug resistance monitoring in PrEP programs and **resistance monitoring** for projects collecting dried blood spots from seroconverters on PrEP.

Find out more at gems.pitt.edu or contact gems@pitt.edu